Several other analysts have also commented on QTRX. JPMorgan Chase & Co. started coverage on Quanterix in a research note on Tuesday. They issued an overweight rating on the stock. Cowen started coverage on Quanterix in a research note on Tuesday. They issued an outperform rating on the stock.
Shares of Quanterix (NASDAQ:QTRX) traded up $0.41 during mid-day trading on Tuesday, reaching $19.49. The company had a trading volume of 72,500 shares, compared to its average volume of 177,867. Quanterix has a twelve month low of $15.56 and a twelve month high of $23.70.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/01/05/quanterix-qtrx-earns-buy-rating-from-analysts-at-btig-research.html.
Quanterix Company Profile
Quanterix Corporation is a United States-based company, which is a developer of tools in high definition diagnostics. The Company offers single molecule array (Simoa) platform, whcich uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.